Endo Business Development On Track For Action
This article was originally published in The Pink Sheet Daily
CEO Rajiv De Silva says the company expects to complete at least one business development transaction in the “near-term” and perhaps two to three within the next 18 months, during the company’s second quarter sales and earnings call.
You may also be interested in...
Without predictive factors to determine who is likely to get a severe post-injection reaction, FDA advisory committees say Endo’s proposed REMS for its long-acting testosterone is unlikely to allay safety concerns.
Former Valeant President De Silva joins Endo in the midst of a challenging year for the company, as two top-selling drugs face generic competition. De Silva will need to reenergize Endo and do so quickly if he is to maintain the early favor he appears to have won from investors.
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.